BACKGROUND: Drug resistance is a major problem in ovarian cancer. Triggering apoptosis using death ligands such as tumour necrosis factor-related apoptosis inducing ligand (TRAIL) might overcome chemoresistance.METHODS: We investigated whether acquired cisplatin resistance affects sensitivity to recombinant human (rh) TRAIL alone or in combination with cisplatin in an ovarian cancer cell line model consisting of A2780 and its cisplatin-resistant subline CP70.RESULTS: Combining cisplatin and rhTRAIL strongly enhanced apoptosis in both cell lines. CP70 expressed less caspase 8 protein, whereas mRNA levels were similar compared with A2780. Pre-exposure of particularly CP70 to cisplatin resulted in strongly elevated caspase 8 protein and mRNA l...
Human ovarian cancer is the most lethal gynecological malignancy. Although cisplatin (CDDP) and pacl...
The efficacy of cisplatin-based chemotherapy in cancer is limited by the occurrence of innate and ac...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
BACKGROUND: Drug resistance is a major problem in ovarian cancer. Triggering apoptosis using death l...
BACKGROUND: Drug resistance is a major problem in ovarian cancer. Triggering apoptosis using death l...
OBJECTIVES: The objectives of this study were to determine the sensitivity of ovarian cancer (OC) ce...
Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clin...
Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clin...
Background: Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in res...
Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in resistance of o...
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cell...
Acquired resistance to chemotherapeutic agents is a common problem in the treatment of cancer. Whils...
The frequent development of cellular resistance to cisplatin in cancer patients is a serious limitat...
The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and model...
Failure to efficiently induce apoptosis contributes to cisplatin resistance in non-small-cell lung c...
Human ovarian cancer is the most lethal gynecological malignancy. Although cisplatin (CDDP) and pacl...
The efficacy of cisplatin-based chemotherapy in cancer is limited by the occurrence of innate and ac...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
BACKGROUND: Drug resistance is a major problem in ovarian cancer. Triggering apoptosis using death l...
BACKGROUND: Drug resistance is a major problem in ovarian cancer. Triggering apoptosis using death l...
OBJECTIVES: The objectives of this study were to determine the sensitivity of ovarian cancer (OC) ce...
Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clin...
Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clin...
Background: Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in res...
Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in resistance of o...
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cell...
Acquired resistance to chemotherapeutic agents is a common problem in the treatment of cancer. Whils...
The frequent development of cellular resistance to cisplatin in cancer patients is a serious limitat...
The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and model...
Failure to efficiently induce apoptosis contributes to cisplatin resistance in non-small-cell lung c...
Human ovarian cancer is the most lethal gynecological malignancy. Although cisplatin (CDDP) and pacl...
The efficacy of cisplatin-based chemotherapy in cancer is limited by the occurrence of innate and ac...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...